摘要
目的分析血必净注射液治疗耐甲氧西林金黄色葡萄球菌(MRSA)所致肺部感染的临床疗效及安全性。方法选取2014年9月—2016年3月武汉市第十一医院呼吸科收治的MRSA所致肺部感染患者82例,随机分为对照组与观察组,每组41例。在对症治疗基础上,对照组患者予以注射用盐酸万古霉素治疗,观察组患者在对照组基础上加用血必净注射液治疗;两组患者均连续治疗10 d。比较两组患者临床疗效、临床症状及体征消失时间、治疗前后血清C反应蛋白(CRP)和降钙素原(PCT)水平、不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。观察组患者退热时间、咳嗽和咳痰消失时间短于对照组(P<0.05);两组患者肺部啰音消失时间、影像学检查结果恢复正常时间比较,差异无统计学意义(P>0.05)。治疗前两组患者血清CRP、PCT水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清CRP、PCT水平低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论血必净注射液治疗MRSA所致肺部感染的临床疗效确切,可快速有效地改善患者临床症状及体征,且安全性较高。
Objective To analyze the clinical effect and safety of xuebijing injection on pulmonary infection caused by methicillin - resistant staphylococcus aureus （MRSA）. Methods From September 2014 to March 2016, a total of 82 patients with pulmonary infection caused by MRSA were selected in the Department of Respiratory Medicine, the 11 th Hospital of Wuhan, and they were randomly divided into control group and observation group, each of 41 cases. Based on conventional treatment, patients of control group received vancomycin hydrochloride for injection, while patients of observation group received vaneomycin bydrochloride for injection combined with xuebijing injection; both groups continuously treated for 10 days. Clinical effect, disappearance time of clinical symptoms and signs, serum level of CRP and PCT before and after treatment, and incidence of adverse reactions were compared between the two groups. Results The clinical effect of observation group was statistically significantly better than that of control group （P 〈 0.05 ）. Disappearance time of fever, cough and expectoration of observation group was statistically significantly shorter than that of control group, respectively （ P 〈 0. 05 ） , while no statistically significant differences of disappearance time of lung tale or recovery time of imaging examination results was found between the two groups （P 〉 0. 05 ）. No statistically significant differences of serum level of CRP or PCT was found between the two groups before treatment （ P 〉 0. 05 ） , while serum levels of CRP and PCT of treatment group were statistically significantly lower than those of control group after treatment （ P 〈 0. 05 ）. No statistically significant differences of incidence of adverse reactions was found between the two groups （ P 〉 0. 05 ）. Conclusion Xuebijing injection has certain clinical effect in treating pulmonary infection caused by MRSA, can quickly and effectively relive the clinical symptoms and signs, with relatively high safety.
出处
《实用心脑肺血管病杂志》
2016年第11期83-85,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
肺疾病
感染
耐甲氧西林金黄色葡萄球菌
血必净注射液
治疗结果
Lung diseases
Infection
Methieillin - resistant staphylococcus aureus
Xuebijing injection
Treatment outcome
